{"@id":"https://bioecon.ru/technology/biotech-ip-valuation/","@type":"Technology","cluster":"regulatory-legal","formats":{"html":"https://en.bioecon.ru/technology/biotech-ip-valuation/","json":"https://en.bioecon.ru/api/v1/technology/biotech-ip-valuation/index.json"},"id":"biotech-ip-valuation","industries":["services"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/services/"],"suppliers":["https://bioecon.ru/companies/tsingke-biotechnology/","https://bioecon.ru/companies/codexis/","https://bioecon.ru/companies/bbca-group/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/granbio/","https://bioecon.ru/companies/life3-biotech/","https://bioecon.ru/companies/huazhi-rice-gene-technology/","https://bioecon.ru/companies/united-therapeutics/","https://bioecon.ru/companies/roche-holding/"]},"maturity":null,"name":"Biotech IP valuation","regions":["us","eu","in","cn"],"risk":"low","section":"technology","sector":"services-governance-capital","sources":[{"date":"2026-07-09","entity":"ocean-tomo","kind":"vendor","urls":[]},{"date":"2026-08-08","entity":"consor-ip-consulting","kind":"vendor","urls":[]},{"date":"2026-08-04","entity":"cra-ip-valuation","kind":"vendor","urls":[]},{"date":"2026-08-11","entity":"everedge-global","kind":"vendor","urls":[]},{"date":"2026-08-05","entity":"aon-ip-solutions","kind":"vendor","urls":[]},{"date":"2026-07-16","entity":"greyb","kind":"vendor","urls":[]},{"date":"2026-08-12","entity":"ktmine","kind":"vendor","urls":[]},{"date":"2026-08-16","entity":"zhongjinhao-asset-appraisal","kind":"vendor","urls":[]},{"date":"2026-05-26","entity":"inngot","kind":"vendor","urls":[]},{"date":"2026-08-16","entity":"china-sciences-exchange-ip","kind":"vendor","urls":[]}],"stages":[{"n":1,"title":"Patent portfolio identification"},{"n":2,"title":"Prior-art and claims analysis"},{"n":3,"title":"Valuation methodology selection"},{"n":4,"title":"Royalty-rate benchmarking"},{"n":5,"title":"Monetary value determination"},{"n":6,"title":"Valuation report delivery"}],"summary":"Consultancies and data platforms that value biotechnology and pharmaceutical patent portfolios for licensing negotiations, M\u0026A, litigation and capital raises — translating a patent estate covering therapeutics, diagnostics or platform technologies into a defensible monetary figure.","url":"/technology/biotech-ip-valuation/","verified":"2026-08-16"}